Evidence map›Paper›PMID 41239440›Full record

ArticleJournal of hematology & oncology2025

B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study.

Tingfei Gu, Zhao Chen, Tianyao Wang, Yujun Dong, Lei Kang

2 registry-linked trialsAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07319897 phase2 / phase3recruitingnot on this map

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

TypeinterventionalSponsorPeking University First HospitalRan2025 to 2027Enrolled300ConditionsMultiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell NeoplasmArms68Ga-BCMA PET/CT
NCT07660939 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET/CT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders

TypeinterventionalSponsorPeking University First HospitalRan2026 to 2027Enrolled50ConditionsPlasma Cell Disorders, Multiple Myeloma (MM)ArmsGPRC5D-Targeted PET/CT Imaging
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Imaging B cell maturation antigen in multiple myeloma.The Journal of clinical investigation · 2026
    Article
  3. Immuno-imaging in solid organ transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tingfei GuDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist, Beijing, 100034, China.
Zhao ChenDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist, Beijing, 100034, China.
Tianyao WangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist, Beijing, 100034, China.
Yujun DongDepartment of Hematology, Peking University First Hospital, Beijing, 100034, China.
Lei KangDepartment of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist, Beijing, 100034, China. kanglei@bjmu.edu.cn.

Funding

Beijing Municipal Science & Technology Commission Z221100007422027Beijing Nova Program 20240484725China Postdoctoral Science Foundation 2024M750132Future Talent Development Plan in the Medical Engineering Field MBZX202502-0029National High Level Hospital Clinical Research Funding Interdisciplinary Research Project of Peking University First Hospital, 2023IR17, 2024IR07, Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital, 2025CX38, 2024CX18, Scientific Research Seed Fund, 2024SF64National Key Research and Development Program of China 2024YFE0113500National Natural Science Foundation of China 82472018, 82171970, 82402320Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0500900
6 · The paper itself

Abstract

B-cell maturation antigen (BCMA)-targeted positron emission tomography/computed tomography (PET/CT) represents a promising tool for the management of multiple myeloma, enabling noninvasive and quantitative evaluation across different disease stages. This novel technique specifically addresses two major diagnostic challenges: the limited specificity of conventional

Indexed as

B-Cell Maturation AntigenMultiple MyelomaPositron Emission Tomography Computed TomographyAgedFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedNeoplasm, ResidualProspective StudiesSingle-Domain AntibodiesB-Cell Maturation AntigenFluorodeoxyglucose F18Single-Domain AntibodiesTNFRSF17 protein, humanB-cell maturation antigenMinimal residual diseaseMultiple myelomaPET/CTTherapy surveillance

Identifiers

PMID41239440
PMCPMC12619229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.